Spinal Muscular Atrophy

Disclaimer: This information is intended for educational purposes and should not be considered medical advice. Clinical decisions must always be made by a qualified healthcare professional, taking into account the individual patient's condition, available resources, and the most current evidence. This content does not replace the need for professional judgment or consultation with medical specialists.

Overview

• Definition: Spinal Muscular Atrophy (SMA) is a genetically determined, autosomal recessive neuromuscular disorder characterized by degeneration of alpha motor neurons in the anterior horn of the spinal cord and brainstem, leading to progressive muscle weakness, atrophy, and hypotonia. It primarily affects proximal muscles, but can impact all voluntary muscles, including those involved in breathing and swallowing.
• Epidemiology:
  • Incidence: Approximately 1 in 10,000 live births worldwide.
  • Carrier Frequency: Approximately 1 in 50 individuals in the general population are asymptomatic carriers of the SMN1 gene mutation.
  • SMA is the most common genetic cause of infant mortality.
• Classification: SMA is traditionally classified into types based on age of onset and maximum motor milestones achieved, though with the advent of genetic testing and therapies, a more nuanced understanding including SMN2 copy number is critical.
  • SMA Type 0 (Prenatal Onset): Severe, often lethal in utero or within the first weeks of life. Characterized by severe hypotonia, arthrogryposis, and respiratory failure at birth.
  • SMA Type 1 (Infantile Onset / Werdnig-Hoffmann Disease): Onset usually before 6 months of age (often within 3 months). Infants never achieve the ability to sit independently. Marked by severe hypotonia, weak cry, poor suck/swallow, profound respiratory distress. Historically, life expectancy was typically less than 2 years without ventilatory support.
  • SMA Type 2 (Intermediate / Dubowitz Disease): Onset typically between 6 and 18 months of age. Children learn to sit independently but never achieve the ability to stand or walk. Features include proximal weakness, fasciculations, scoliosis, and respiratory involvement. Variable life expectancy, often into adulthood with supportive care.
  • SMA Type 3 (Juvenile Onset / Kugelberg-Welander Disease): Onset after 18 months, often in childhood or adolescence. Patients achieve independent ambulation at some point, but may lose it later in life. Characterized by proximal muscle weakness, difficulty running, climbing stairs, and occasional mild respiratory/bulbar involvement. Normal life expectancy with varying degrees of disability.
  • SMA Type 4 (Adult Onset): Onset typically after age 30, with very slow progression. Mild to moderate proximal muscle weakness, usually preserving ambulation. Normal life expectancy.

Pathophysiology

• Mechanism: SMA is caused by a deficiency in the Survival Motor Neuron (SMN) protein, crucial for the health and function of motor neurons.
  • Genetic Basis: In over 95% of cases, SMA is caused by a homozygous deletion or mutation in the SMN1 gene (telomeric SMN gene) located on chromosome 5q13.
  • SMN Protein: The SMN1 gene produces a full-length, functional SMN protein. A paralogous gene, SMN2 (centromeric SMN gene), also produces SMN protein, but due to a critical nucleotide difference (C to T transition) in exon 7, most of the protein produced by SMN2 is a truncated, unstable, non-functional isoform (SMNΔ7). A small percentage (typically 10-15%) of SMN2 transcripts are correctly spliced to produce full-length SMN protein.
  • Correlation with Severity: The number of SMN2 gene copies inversely correlates with disease severity. More SMN2 copies generally lead to higher levels of functional SMN protein, resulting in a milder phenotype (e.g., Type 1 typically has 1-2 SMN2 copies; Type 2 usually 2-3; Type 3 usually 3-4; Type 4 typically 4+).
  • Motor Neuron Degeneration: Insufficient functional SMN protein leads to the degeneration of alpha motor neurons in the spinal cord and brainstem, which transmit signals from the brain to muscles. This results in progressive muscle denervation, atrophy, and weakness. While primarily a motor neuron disease, SMN protein is ubiquitously expressed, and other systems (e.g., cardiac, gastrointestinal) may also be affected, though less overtly.
• Risk Factors:
  • Genetic Inheritance: Autosomal recessive pattern. The primary risk factor is inheriting two defective copies of the SMN1 gene, one from each carrier parent. If both parents are SMN1 carriers, there is a 25% chance with each pregnancy for the child to have SMA, a 50% chance to be a carrier, and a 25% chance to be unaffected and not a carrier.
  • No known environmental or lifestyle risk factors.
• Protective Factors:
  • High SMN2 Copy Number: The presence of more SMN2 gene copies is the most significant natural modifier of disease severity, leading to a milder clinical phenotype due to increased production of functional SMN protein.

Clinical Presentation

Signs and Symptoms

• Cardinal Features:
  • Progressive, symmetrical, generalized muscle weakness, typically more pronounced proximally than distally.
  • Hypotonia (decreased muscle tone).
  • Muscle atrophy (wasting).
  • Absent or significantly reduced deep tendon reflexes (areflexia or hyporeflexia).
  • Tongue fasciculations (fine, rapid, worm-like movements of the tongue) – a highly specific sign, especially in infants.
  • Fine tremors of the outstretched fingers.
• Early Signs (Type 1):
  • Onset typically before 6 months of age.
  • Severe generalized hypotonia ("floppy infant").
  • Weak cry and cough.
  • Poor suck and swallow reflex, leading to feeding difficulties and failure to thrive.
  • Shallow, labored breathing (paradoxical breathing: abdominal protrusion during inspiration, chest retraction).
  • Lack of head control; inability to achieve motor milestones like rolling or sitting.
  • Alert and responsive facies, often described as "bright-eyed."
• Advanced Signs (Type 1 & 2):
  • Severe respiratory insufficiency requiring ventilatory support.
  • Aspiration pneumonia due to bulbar weakness.
  • Severe scoliosis and other orthopedic deformities (e.g., hip dislocation, joint contractures).
  • Progressive loss of motor function, leading to complete immobility.
  • Nutritional deficiencies and weight loss.
• Atypical Presentations:
  • Adult-onset (Type 4): Often presents with subtle, slowly progressive proximal leg weakness, typically after age 30. May experience muscle cramps, fasciculations. Ambulation is usually maintained.
  • Some patients with atypical mutations or other neuromuscular disorders can mimic SMA, necessitating careful diagnostic workup.

Physical Examination

• Inspection:
  • General: Observation of overall muscle bulk, symmetry, posture. In infants, "frog-leg" posture.
  • Musculoskeletal: Evidence of muscle atrophy (especially proximal limbs and trunk). Bell-shaped chest wall (due to diaphragmatic breathing with weak intercostals). Scoliosis or kyphoscoliosis (common in Type 2, 3). Joint contractures.
  • Head and Neck: Lack of head control (infants). Tongue fasciculations (best observed with tongue at rest, after few minutes).
  • Respiratory: Paradoxical breathing (retraction of the chest wall during inspiration), tachypnea, weak cough.
• Palpation: Assessment of muscle tone (hypotonia), muscle bulk (decreased).
• Special Tests:
  • Motor Function Scales: Crucial for baseline assessment and monitoring disease progression and treatment response.
    • CHOP-INTEND (Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders): For infants with Type 1 SMA.
    • Hammersmith Functional Motor Scale-Expanded (HFMSE): For ambulant and non-ambulant children with Type 2 and 3 SMA.
    • Revised Upper Limb Module (RULM): Specific for upper limb function in non-ambulant SMA patients.
    • 6-Minute Walk Test (6MWT): For ambulant patients with SMA.
  • Deep Tendon Reflexes: Typically absent or severely diminished (areflexia/hyporeflexia) in all affected limbs.
  • Cranial Nerves: Assess for facial weakness, bulbar weakness (swallowing, speech), tongue fasciculations. Ocular movements are typically spared.

Diagnostic Approach

History Taking

• Key Questions:
  • Family History: Any family history of muscle weakness, neurological disorders, or known SMA. Consanguinity.
  • Prenatal/Perinatal History: Fetal movements (reduced in Type 0). Birth complications.
  • Developmental Milestones: Age of onset of symptoms. Detailed inquiry about achieved and lost motor milestones (e.g., head control, rolling, sitting, standing, walking, climbing stairs).
  • Progression: Rate and pattern of weakness progression.
  • Feeding/Swallowing: Presence of dysphagia, choking, prolonged feeding times, recurrent aspiration.
  • Respiratory Symptoms: Weak cry, cough, shortness of breath, recurrent respiratory infections, paradoxical breathing, snoring, sleep apnea symptoms.
  • Other Symptoms: Muscle cramps, fatigue, scoliosis progression, joint stiffness.
• Red Flags:
  • Progressive hypotonia and weakness in an infant.
  • Loss of previously achieved motor milestones.
  • Recurrent respiratory infections or unexplained feeding difficulties in an infant/child.
  • Any "floppy infant" with an alert mind.

Laboratory Tests

• First-Line:
  • Creatine Kinase (CK): Often normal or mildly elevated (up to 2-3 times upper limit of normal). This helps differentiate SMA from muscular dystrophies where CK levels are typically much higher.
  • Genetic Testing for SMN1 gene deletion: This is the gold standard diagnostic test. Quantitative Polymerase Chain Reaction (qPCR) is commonly used to detect the homozygous deletion of exon 7 of the SMN1 gene.
• Confirmatory:
  • Genetic Testing for SMN1 deletion: A positive test (homozygous deletion of SMN1 exon 7) confirms the diagnosis in about 95% of SMA patients.
  • SMN2 copy number determination: This is crucial for prognosis and treatment selection, as it correlates with disease severity. It is usually performed concurrently with SMN1 testing.
  • If SMN1 deletion negative: Sequence analysis of the SMN1 gene to detect subtle point mutations or small deletions/insertions (accounts for 5% of SMA cases).
  • Electromyography (EMG) and Nerve Conduction Studies (NCS): Not typically needed if genetic testing is positive, but can be helpful in atypical cases or to rule out other neuromuscular disorders. EMG in SMA typically shows denervation potentials (fibrillations, positive sharp waves) and chronic neurogenic changes (large amplitude, long duration motor unit potentials with reduced recruitment). NCS are usually normal or show slightly reduced compound muscle action potential (CMAP) amplitudes with normal conduction velocities.
• Monitoring:
  • No specific blood tests for monitoring SMA progression itself, but periodic checks for complications:
    • Nutritional status (albumin, prealbumin, vitamins).
    • Respiratory function (pulmonary function tests, blood gas analysis, oximetry).
    • Bone density (due to immobility and potential corticosteroid use with gene therapy).

Imaging

• Recommended: No imaging is used for the primary diagnosis of SMA. Imaging is used to assess complications:
  • Spine Radiographs: To monitor for scoliosis progression and guide orthopedic management.
  • Chest X-ray/CT Scan: To assess for atelectasis, pneumonia, or other pulmonary complications, and to evaluate for chest wall deformities.
  • Barium Swallow Study/Videofluoroscopic Swallowing Study: To assess for dysphagia and aspiration risk.
• Advanced: Not directly for SMA diagnosis. Brain MRI typically normal, may show non-specific white matter changes in some cases.

Management

Acute Management

• Immediate:
  • Respiratory Support: In infants with Type 1 SMA or any patient experiencing acute respiratory distress, immediate respiratory assessment and support are paramount. This may include oxygen supplementation, non-invasive ventilation (NIV) via BiPAP/CPAP, or intubation and mechanical ventilation for severe respiratory failure.
  • Airway Clearance: Aggressive airway clearance techniques (e.g., assisted cough, mechanical insufflation-exsufflation devices) to prevent atelectasis and pneumonia.
• Stabilization:
  • Nutritional Support: For patients with dysphagia or failure to thrive, ensure adequate caloric and fluid intake. This may involve nasogastric tube feeding initially, progressing to gastrostomy tube placement for long-term support.
  • Infection Management: Prompt treatment of respiratory infections with antibiotics.
• Emergency:
  • Acute Respiratory Failure: Leading cause of mortality in severe SMA. Requires immediate medical attention, often involving ICU admission for ventilatory support.
  • Severe Aspiration: Can lead to acute pneumonia; requires airway protection, antibiotics, and consideration of long-term feeding solutions.

Chronic Management

SMA management is multidisciplinary, focusing on disease modification and comprehensive supportive care. - Pharmacological (Disease-Modifying Therapies): - Nusinersen (Spinraza®): - Mechanism: Antisense oligonucleotide that modifies SMN2 splicing to increase production of full-length SMN protein. - Administration: Intrathecal injection into the cerebrospinal fluid (CSF). - Dosing: 12 mg/dose. - Loading Doses: Four doses administered on Days 0, 14, 28, and 63. - Maintenance Doses: One dose every 4 months thereafter. - Indications: Approved for all types of SMA in pediatric and adult patients. - Adverse Effects: Most common are related to the lumbar puncture procedure (headache, back pain). Serious risks include hydrocephalus, infections, and bleeding. - Onasemnogene abeparvovec (Zolgensma®): - Mechanism: AAV9-based gene therapy that delivers a functional copy of the human SMN1 gene into motor neuron cells. - Administration: One-time intravenous infusion. - Dosing: 1.1 x 10^14 vg/kg. - Indications: Approved for pediatric patients younger than 2 years of age with SMA. Some countries have broader age/weight indications. Pre-symptomatic treatment is most effective. - Adverse Effects: Elevated liver enzymes and acute liver injury (requires corticosteroid pre-treatment and monitoring: e.g., prednisolone 1 mg/kg/day for 1 month, starting 24h prior to infusion). Thrombocytopenia, troponin elevation, vomiting. - Risdiplam (Evrysdi®): - Mechanism: Small molecule SMN2 splicing modifier taken orally, increasing production of full-length SMN protein. - Administration: Daily oral liquid. - Dosing: Based on weight. - For patients weighing <20 kg: 0.25 mg/kg orally once daily. - For patients weighing ≥20 kg: 0.5 mg orally once daily. - Indications: Approved for patients aged 2 months and older with SMA. - Adverse Effects: Most common include fever, diarrhea, rash, upper respiratory tract infection. Less common but serious: thrombocytopenia, kidney stone formation. - Non-pharmacological: - Respiratory Care: - Regular pulmonary function testing. - Airway clearance techniques (percussion, postural drainage, cough assist devices). - Non-invasive ventilation (NIV) for nocturnal hypoventilation or daytime respiratory support. - Immunizations: Annual influenza vaccine, pneumococcal vaccines (PCV13, PPSV23). - Nutritional Care: - High-calorie, nutrient-dense diet to prevent malnutrition. - Gastrostomy tube placement for persistent feeding difficulties, aspiration risk, or to ensure adequate caloric intake. - Management of constipation (common due to immobility and weak abdominal muscles). - Physical Therapy (PT): - To maintain range of motion, prevent contractures, and strengthen preserved muscles. - Stretching, passive and active exercises. - Hydrotherapy. - Occupational Therapy (OT): - Adaptive equipment to maximize independence in daily activities (e.g., seating, bathing, dressing aids). - Wheelchair prescription and training. - Speech and Swallowing Therapy: - For bulbar weakness, to improve speech clarity and safe swallowing. - Regular swallowing assessments. - Orthopedic Care: - Monitoring and management of scoliosis (bracing, spinal fusion surgery if severe and progressive). - Management of joint contractures (stretching, splinting, sometimes surgical release). - Prevention of hip dislocation. - Rehabilitation: Comprehensive rehabilitation programs tailored to patient's functional level. - Palliative Care: Early integration for severe types to focus on symptom management, quality of life, and family support. - Monitoring: - Regular assessments by a multidisciplinary team (neurologist, pulmonologist, gastroenterologist, orthopedist, physical/occupational/speech therapists). - Scheduled evaluations of motor function using validated scales (CHOP-INTEND, HFMSE, RULM, 6MWT). - Regular respiratory function tests, oximetry. - Nutritional status, weight, growth. - Bone density scans (DEXA) due to increased fracture risk. - Developmental assessments.

Treatment Algorithms

• First-Line: All patients with genetically confirmed SMA (homozygous SMN1 deletion or biallelic SMN1 mutations) should be evaluated for disease-modifying therapies regardless of age or severity. Early treatment (especially pre-symptomatic or in infancy) yields the best outcomes.
  • The choice between Nusinersen, Onasemnogene abeparvovec, and Risdiplam is complex and depends on factors such as:
    • Patient age and weight (Onasemnogene abeparvovec is generally for younger, smaller children).
    • SMA type and symptom severity.
    • SMN2 copy number.
    • Accessibility to intrathecal injections or IV infusions.
    • Patient/family preference and lifestyle (e.g., daily oral vs. injections vs. one-time infusion).
    • Insurance coverage and local regulations.
• Second-Line: No standard "second-line" agent for SMA. However, some clinicians consider combining therapies or switching therapies in specific circumstances, though evidence for combination therapy is still emerging. E.g., patients initially treated with Nusinersen may consider adding Risdiplam or vice-versa, or moving to Onasemnogene abeparvovec if eligible. This should be done in consultation with experts and considering emerging evidence.
• Refractory Cases: For patients who do not respond adequately to initial therapy or experience significant side effects, re-evaluation of the diagnosis, optimization of supportive care, and consideration of investigational therapies (clinical trials) are options. Palliative care should be prioritized to maximize comfort and quality of life.

Complications

• Common:
  • Respiratory infections (pneumonia, bronchitis).
  • Aspiration pneumonia due to dysphagia.
  • Scoliosis and kyphoscoliosis (especially Type 2 and 3).
  • Joint contractures (ankles, knees, hips, elbows) due to immobility and muscle imbalance.
  • Feeding difficulties, failure to thrive, malnutrition, constipation.
  • Bone demineralization and fractures.
  • Fatigue, muscle cramps.
• Serious:
  • Acute and chronic respiratory failure (leading cause of mortality in severe SMA).
  • Severe dysphagia with high risk of aspiration.
  • Severe scoliosis leading to restrictive lung disease.
  • Acute liver injury (with Onasemnogene abeparvovec).
  • Hydrocephalus (rare, with Nusinersen).
• Long-term:
  • Permanent motor impairment, ranging from inability to ambulate to complete immobility.
  • Chronic pain from orthopedic deformities.
  • Dependency on assistive devices (wheelchairs, ventilators).
  • Psychosocial challenges related to chronic illness and disability.

Prognosis

• Factors Affecting Outcome:
  • SMA Type / SMN2 Copy Number: Higher SMN2 copy numbers and later onset generally correlate with milder phenotypes and better prognosis.
  • Age at Diagnosis and Treatment Initiation: Earlier diagnosis and pre-symptomatic treatment initiation with disease-modifying therapies significantly improve motor outcomes and survival, especially in Type 1 SMA.
  • Access to Comprehensive Supportive Care: High-quality respiratory, nutritional, orthopedic, and rehabilitative care can drastically improve quality of life and prolong survival.
• Survival:
  • Historically, Type 1 SMA led to death or permanent ventilation by 2 years of age in 90% of cases. With disease-modifying therapies, survival is dramatically improved, with many patients achieving motor milestones previously impossible.
  • Type 2 and 3 SMA have variable life expectancy, often into adulthood, but with progressive disability. Treatment has shown to stabilize or improve motor function and reduce the need for respiratory support.
  • Type 4 SMA has a normal life expectancy with mild, slowly progressive weakness.
• Quality of Life:
  • With modern treatments and comprehensive care, the focus has shifted from mere survival to maximizing motor function, independence, and overall quality of life. Patients are achieving milestones like sitting, standing, and walking, which were unimaginable before these therapies.
  • However, SMA remains a chronic, progressive condition, and patients typically require lifelong management and support.

Prevention

• Primary Prevention (Preventing initial occurrence):
  • Carrier Screening: Pre-conception or prenatal genetic carrier screening for SMN1 mutations is available, particularly for individuals with a family history of SMA or in populations with high carrier rates. This allows at-risk couples to make informed reproductive decisions.
  • Prenatal Diagnosis: For at-risk pregnancies, chorionic villus sampling (CVS) or amniocentesis can be performed to diagnose SMA prenatally.
  • Preimplantation Genetic Diagnosis (PGD): For couples undergoing in vitro fertilization (IVF) who are both carriers, PGD can be used to select embryos unaffected by SMA.
• Secondary Prevention (Early detection and intervention):
  • Newborn Screening (NBS): Increasingly adopted in many regions, NBS identifies infants with SMA before symptom onset. This allows for pre-symptomatic initiation of disease-modifying therapies, which has been shown to be critical for achieving optimal motor outcomes and preventing irreversible motor neuron loss. SMN1 deletion testing is typically performed via dried blood spot analysis.
• Tertiary Prevention (Preventing complications):
  • Early and consistent application of disease-modifying therapies.
  • Proactive and comprehensive multidisciplinary supportive care to prevent, monitor, and manage respiratory, nutritional, and orthopedic complications.

Special Populations

• Pediatric:
  • Infants and Children: The majority of SMA cases. Early diagnosis (ideally via newborn screening) and prompt initiation of disease-modifying therapy are paramount. Care requires a highly specialized multidisciplinary team. Growth and development, feeding, and respiratory function are critical monitoring points.
• Geriatric:
  • SMA Type 4 is an adult-onset form, but it's not typically a geriatric disease. However, adults with Type 2 or 3 SMA are living longer due to improved care and therapies. Management focuses on maintaining function, managing comorbidities, and addressing age-related health issues in the context of SMA-related weakness and disability.
• Pregnancy:
  • Women with SMA (typically Type 3 or 4) can become pregnant. Pregnancy can exacerbate respiratory insufficiency and physical weakness due to increased physiological demands.
  • Close monitoring of respiratory function and physical capabilities is essential.
  • Genetic counseling for the risk of passing SMA to offspring is crucial.
  • Pharmacological treatment decisions (Nusinersen, Risdiplam) during pregnancy should be made on a case-by-case basis, weighing risks and benefits, with limited data available. Onasemnogene abeparvovec is not indicated.
• Comorbidities:
  • Management of SMA patients with other chronic conditions requires careful coordination. For example, cardiac issues (rarely primary SMA related), diabetes, or renal impairment.
  • Drug interactions between SMA therapies and medications for comorbidities should be reviewed. Mobility limitations and respiratory compromise can impact the management of other conditions.

Clinical Pearls

• Diagnostic:
  • "Floppy baby with bright eyes": This classic description should immediately raise suspicion for SMA Type 1. The infant is severely hypotonic and weak, but typically alert and interactive.
  • Tongue Fasciculations: While sometimes subtle, tongue fasciculations are a highly specific and important diagnostic clue, especially in infants.
  • Proximal Weakness > Distal: The pattern of weakness is typically more severe in proximal muscles (shoulders, hips) than distal muscles.
  • Genetic Testing is Key: SMN1 gene deletion analysis is the definitive diagnostic test. Do not delay genetic testing while awaiting EMG/NCS or other studies if clinical suspicion is high.
• Treatment:
  • Time is Motor Neuron: Early diagnosis and initiation of disease-modifying therapies (Nusinersen, Onasemnogene abeparvovec, Risdiplam) are critical to preserve motor neurons and maximize functional outcomes.
  • Multidisciplinary Approach: Effective management requires a comprehensive team including neurologists, pulmonologists, gastroenterologists, orthopedists, and various therapists.
  • Holistic Care: Disease-modifying therapies are transformative but do not replace the need for excellent supportive care (respiratory, nutritional, orthopedic, rehabilitation).
• Pitfalls:
  • Diagnostic Delay: Misdiagnosing SMA as benign hypotonia, cerebral palsy, or other neuromuscular disorders can lead to delayed treatment and irreversible motor neuron loss.
  • Underestimating Respiratory Involvement: Respiratory insufficiency is the leading cause of morbidity and mortality. Regular monitoring and proactive management are crucial, even in milder types.
  • Neglecting Orthopedic Complications: Scoliosis and contractures can significantly impact function and quality of life if not managed early and aggressively.
  • Over-reliance on Drug Therapy Alone: While highly effective, disease-modifying drugs do not cure SMA and must be integrated with robust supportive care.

Recent Updates

• Guidelines:
  • Universal Newborn Screening: Growing endorsement and implementation of universal newborn screening for SMA in many countries and regions, allowing for pre-symptomatic diagnosis and treatment.
  • Updated Treatment Guidelines: Guidelines from organizations like the American Academy of Neurology (AAN), SMA Foundation, and various international consortia continue to be updated to reflect the evolving landscape of disease-modifying therapies and best practices in supportive care.
• Evidence:
  • Long-term Efficacy and Safety Data: Continued collection and publication of long-term data for Nusinersen, Onasemnogene abeparvovec, and Risdiplam, confirming their sustained benefits in motor function and survival across different SMA types and ages.
  • Real-World Evidence: Increasing real-world data reinforces the findings from clinical trials and provides insights into the effectiveness of these therapies in diverse clinical settings.
  • Emerging Therapies: Research continues into novel therapeutic approaches, including other gene therapies, combination therapies, and drugs targeting different aspects of SMA pathophysiology.
• Controversies:
  • Optimal Sequencing and Combination of Therapies: Debates exist regarding the optimal order, or potential benefits, of combining existing disease-modifying therapies. Evidence is still accumulating in this area.
  • Long-term Safety of Gene Therapy: While generally well-tolerated, the very long-term safety profile of AAV-mediated gene therapy (Onasemnogene abeparvovec) is still being monitored.
  • Access to Treatment: The high cost of disease-modifying therapies continues to be a global challenge, raising ethical and practical questions about equitable access.
  • Treatment of Adults with SMA: While approved, the efficacy and optimal management strategies for adult-onset SMA (especially Type 3 and 4) are still being refined with new data.

Key References

• Guidelines:
  • Mercuri E, et al. Diagnosis and management of spinal muscular atrophy: Part 1: Recommendations for diagnosis, rehabilitation, orthopedic and nutritional care. Neuromuscul Disord. 2018 Feb;28(2):103-115.
  • Mercuri E, et al. Diagnosis and management of spinal muscular atrophy: Part 2: Respiratory, cardiac, bone health, and anaesthesia care. Neuromuscul Disord. 2018 Feb;28(2):116-127.
  • Wang CH, et al. Consensus Statement for Standard of Care in Spinal Muscular Atrophy. J Child Neurol. 2021 Mar;36(3):149-165. (An updated version or similar international consensus may exist)
  • American Academy of Pediatrics (AAP) Clinical Practice Guidelines on Spinal Muscular Atrophy. (Regularly updated on relevant topics like newborn screening).
• Studies (Landmark Clinical Trials):
  • Nusinersen:
    • Finkel RS, et al. Nusinersen versus Sham Control in Infantile Spinal Muscular Atrophy. N Engl J Med. 2017 Nov 2;377(18):1723-1732. (ENDEAR trial)
    • Mercuri E, et al. Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy. N Engl J Med. 2018 Jun 21;378(25):2348-2349. (CHERISH trial)
  • Onasemnogene abeparvovec:
    • Mendell JR, et al. AAV9 Intrathecal Gene Therapy for Spinal Muscular Atrophy. N Engl J Med. 2017 Nov 2;377(18):1713-1722. (STRIVE trial for Type 1)
    • Day JW, et al. Onasemnogene Abeparvovec Gene Therapy for Older Patients with Spinal Muscular Atrophy. N Engl J Med. 2021 Mar 18;384(11):1021-1033. (SPRINT, SURPASS trials for pre-symptomatic and later-onset SMA)
  • Risdiplam:
    • Baranello G, et al. Risdiplam in Type 1 Spinal Muscular Atrophy. N Engl J Med. 2021 Mar 18;384(11):993-1007. (FIREFISH Part 2)
    • Mercuri E, et al. Risdiplam in Types 2 and 3 Spinal Muscular Atrophy. N Engl J Med. 2022 Mar 10;386(10):917-927. (SUNFISH Part 2)
• Reviews:
  • Prior TW. Spinal Muscular Atrophy. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2024. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1352/ (Regularly updated, highly comprehensive).
  • Finkel RS. New Approaches to Spinal Muscular Atrophy. Annu Rev Med. 2023 Jan 27;74:363-380.
  • Collaborative International Research in SMA (CURE SMA) and SMA Foundation websites (www.curesma.org, www.smafoundation.org) provide patient-friendly and professional resources.